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Abstract 
Background: Chronic kidney disease is a growing health problem on a global scale. The 
increasing prevalence of chronic kidney disease presents an urgent need to better understand the 
knowledge, confidence and engagement in self-managing the disease.  
Objectives: This study examined group differences in patient activation and health-related 
quality of life, disease-specific knowledge, self-management, and confidence with managing 
chronic disease across all 5 stages of chronic kidney disease.  
Design: The study employed a descriptive correlational design.  
Settings: Participants were recruited from five primary care, three nephrology clinics, and one 
dialysis center in two Midwestern cities in the United States.  
Participants: The convenience sample included 85 adults with hypertension, diabetes mellitus, 
and chronic kidney disease, including kidney failure, who spoke English.  
Measurements:  Seven measurements were used to collect data via telephone interviews with 
participants not receiving hemodialysis, and face-to-face interviews with those receiving 
hemodialysis at the beginning of their treatment session.  
Results: Analyses indicated that half the participants were female (50.58%), the mean age was 
63.21years (SD = 13.11), and participants with chronic kidney disease stage 3 were the most 
activated. Post hoc differences were significant in patient activation and blood pressure self-
management and anxiety across chronic kidney disease stages, excluding stage 5 (kidney 
failure).  
Conclusion: The study supports the critical need to activate patients in the self-management of 
chronic kidney disease. Additionally, it is important for healthcare providers and patients to 
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develop strategies that will maintain patients’ health-related quality of life as kidney disease 
progresses.  
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Patient Activation with Knowledge, Self-Management, and Confidence  
in Chronic Kidney Disease  
CKD is a global health concern (Levey et al., 2007) associated with the increased 
prevalence of diabetes mellitus and hypertension worldwide (World Health Organization, 2012). 
The increasing incidence in CKD diagnosis is a major public health problem (Kidney Disease 
Improving Global Outcomes [KDIGO], 2013; United States Renal Data Systems [USRDS], 
2014). Amazingly 93% of Americans have a lifetime risk for developing CKD stage 3, followed 
by 12% and 4% for CKD stages 4 and 5, respectively (Grams, Chow, Segev, & Coresh, 2013). 
National initiatives like Healthy People 2020 include CKD as a focus area and global initiatives, 
like the World Kidney Day, heighten CKD awareness worldwide (World Kidney Day, 2015). 
In the United States there are 26 million adults afflicted with CKD. Diabetes mellitus 
(DM) and hypertension (HTN) are the two most common causes of (Bakris et al., 2010; KDIGO, 
2013) and many people are diagnosed with all three conditions (National Kidney Foundation 
[NKF], 2013). Increasing costs, morbidity, and mortality presents a compelling need to better 
understand how to help this population self-manage the disease to prevent and/or slow 
progression (NKF, 2013; USRDS, 2014).  
Enhancing knowledge, developing self-management skills, and building confidence are 
considered to be important variables associated with improving outcomes, including health-
related quality of life (HRQoL), among patients with chronic disease (Bandura, 2004; Lorig, 
Ritter, Villa, & Armas, 2009). The Patient Activation Measure is often used to measure patients’ 
knowledge, skills and confidence related to managing their health care (Hibbard, Stockard, 
Mahoney, & Tusler, 2004; Hibbard, Mahoney, Stockard, & Tusler, 2005). The increasing 
prevalence of CKD makes investigating patient activation across all 5 CKD stages a priority to 
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delay disease progression and associated health complications, like cardiovascular disease. 
Activation has not been described in any CKD stage and we don’t know if differences exist 
across the stages, thus the purpose of this study was to describe patient activation, HRQoL, 
knowledge, self-management (SM), and confidence in the patients with CKD, including those 
who have kidney failure. The specific aim was to examine if differences exist in patient 
activation, and HRQoL, knowledge, SM, and confidence across CKD stages.  
Background  
This study was guided by the theoretical concepts of patient activation and medical self-
management. The conceptual underpinnings of patient activation with chronic disease 
management include self-efficacy, SM, and readiness to change health-related behaviors 
(Hibbard et al., 2004).  Activated patients use knowledge, skills, and confidence to manage their 
health (Hibbard et al., 2004, 2005). Activated patients, compared to those who are not, tend to 
participate in more health promotion activities, like engaging in routine exercise or receiving 
annual eye exams (Rask et al., 2009), experience fewer hospitalizations (Begum, Donald, 
Ozolins, & Dower, 2011), and show improvement with their hemoglobin A1c scores in the DM 
population (Remmers et al., 2009). Activation exists on a continuum where patients move 
between four levels depending on their health, confidence, willingness to engage, and life 
situations. Attaining activation is an iterative process and higher levels indicate greater activation 
(Hibbard et al., 2004; Remmers et al., 2009).  
CKD decreases HRQoL over time. As CKD progresses to kidney failure, patients may 
experience a decline in their general health, including physical and social functioning, while 
experiencing more pain (Kaltsouda et al., 2011; Pagels, Soderkvist, Medlin, Hylander, & Heiwe, 
2012). Patients as early as CKD stage 2 begin to experience a decline in their physical function, 
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vitality and energy, social function, mental health and emotional well-being when compared to a 
cohort of people of the same age and gender without kidney disease (Pagels et al., 2012).  
CKD knowledge includes understanding how the kidneys function and recognizing 
symptoms associated with disease progression (Wright, Wallston, Elasy, Ikizler, & Cavanaugh, 
2011). Teaching patients to manage their CKD is an important part of preserving kidney function 
(Thomas, 2009). For example, patients need to be taught that maintaining appropriate BP 
readings (Fraser et al., 2013), tight BG control (Reidy, Kang, Hostetter, & Sustak, 2014), along 
with medication adherence all work together to protect their kidney health (Thomas, 2009). 
Patients with CKD who have a poor understanding of their disease process tend to participate 
less in their health care management, which includes making future decisions about dialysis 
treatment (Wright-Nunes et al., 2013).  
Developing core SM skills, such as problem-solving, decision making, action planning, 
goal-setting, patient/healthcare provider partnership and resource utilization (Welch et al., 2014) 
is central to improving adherence to daily SM behaviors. Reading food labels, healthy eating 
(Lorig et al., 2009), enhancing communication between patients and their healthcare providers, 
and improving medication taking (Welch et al., 2014) are essential SM behaviors of chronic 
disease management. 
Self-efficacy, or confidence, is having the ability to perform an action to achieve a goal 
(Bandura, 2004). Developing confidence is core to engaging in SM behaviors for chronic disease 
management (Barnason et al., 2003; Curtin et al., 2008). Self-efficacy increases over time and is 
associated with positive health outcomes, like risk factor modifications in coronary artery disease 
(Barnason et al., 2003), increased physiological and psychosocial functioning in heart and kidney 
failure patients (Barnason et al., 2003; Curtin et al., 2008), improved SM behaviors and 
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medication adherence in CKD patients (Curtin et al., 2008), and decreased weight gain in 
patients receiving dialysis (Tsay, 2003).  
In summary, activated individuals are equipped with the knowledge, skills and 
confidence necessary for daily SM of chronic conditions. However, no studies to date have 
reported if differences exist across CKD stages in patient activation and findings from this study 
will begin to fill this gap. 
Methods  
Setting and Sample  
This study used a descriptive correlational design. Eligible participants were at least 19 
years old, diagnosed with CKD, DM and HTN, able to speak and read English and provide 
informed consent, and had access to a telephone and US mail. After receiving Institutional 
Review Board approval, participants were initially recruited from four primary care clinics, two 
nephrology clinics, and a dialysis center in a Midwestern city. Healthcare providers assisted with 
recruitment. Twenty-five out of 41 participants completed the surveys by US mail or Survey 
Monkey. Additional sites along with research assistants were added to increase participant 
enrollment. The new sites included a diabetic clinic and a nephrology clinic in another 
Midwestern city within the same state. Three new surveys were added to better understand 
patients’ medical SM, and confidence in chronic disease management. Research assistants were 
trained regarding participant recruitment, data collection, and human subjects’ protection. Data 
were collected via telephone interviews for participants not receiving hemodialysis; face-to-face 
interviews were conducted with patients receiving hemodialysis during their treatment sessions. 
All interviews lasted 45 to 60 minutes. An addition of 60 participants for a total convenience 
sample of 85 adults across all 5 CKD stages were used for analysis in this study.  
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Measures 
The 13-item Patient Activation Measure uses a 5-point Likert scale, where higher scores 
indicate higher levels of activation. Scores range from 0-100. Cronbach’s α was reported as .87 
and equaled .88 for this study’s sample. Two-week test-retest reliability reported 93% of 
participants within the 95% confidence interval. Three expert judges categorized 10 participants 
as low or high activation; the Cohen’s kappa for the judges’ measured activation levels were .80, 
.90 and .90 (Hibbard et al., 2004, 2005).   
HRQoL was assessed using the Patient Reported Outcomes Measurement Information 
Systems (PROMIS)-29 item profile. A high score corresponds to high levels of the construct 
being measured. Construct validity was tested against an established measure, the Short Form-36 
(SF-36). All domains of the PROMIS-29 were moderately to highly correlated with the SF-36, 
i.e. physical function (r = .86), anxiety (r = -.50), and depression (r = -.70) (National Institutes of 
Health, n.d.). 
Disease-specific knowledge was assessed using two measures, the Kidney Knowledge 
Survey (KiKS) and the Blood Pressure Knowledge Scale (revised) (BPKS). The KiKS is a 28-
item measure. Scoring is determined by the number of correct answers; a higher score equals 
greater knowledge. Kuder-Richardson-20 was reported as .72. Cronbach’s α = .84 for this 
study’s sample. Face and content validity were reviewed by kidney disease experts; construct 
validity was documented by comparing KiKS scores with knowledge scores of similar patient 
characteristics and diagnoses of other chronic diseases, like DM (Wright et al., 2011).  
The BPKS (revised)-11-item scale uses a 7-point Likert scale. A sum score is computed; 
higher scores indicate greater knowledge of BP SM. Scores range from 7 to 77.  Cronbach’s α 
was reported as .85 and equaled .77 for this study’s sample. Content validity was documented by 
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African American women as focus group participants. Three experts reported the items as 
relevant (Peters & Templin, 2008).  
Two measures were used to describe SM of comorbid conditions (HTN and CKD), the 
Blood Pressure Self-Care Scale (revised) (BPSCS) and the CKD Self-Management Scale. The 
BPSCS (revised)-10-item scale uses a 7-point Likert scale. A sum score is computed; higher 
scores reflect greater BP self-care. Scores range from 7 to 70. The reported revised scale’s 
Cronbach’s α (.57) differs from the original scale’s Cronbach’s α (.71) due to poor item-total 
correlation of two items added to the revised scale that focused on drinking alcohol and smoking 
tobacco  (Peters & Templin, 2008). Cronbach’s α = .77 for this study’s sample.  
CKD Self-Management Scale is a newly developed 15-item scale designed to measure 
CKD SM in patients diagnosed with CKD stage 3. The measure uses a 6-point Likert scale. The 
last option, not applicable, was counted as missing data. A sum score is computed; higher scores 
reflect greater SM. Scores range from 15 to 75. One item, “I understand my fluid restriction”, 
was removed for this study given that not all patients with CKD follow a fluid restriction. 
Cronbach’s α = .85 for this study’s sample. Content validity was established by an expert panel 
of four nephrologists, four nurse practitioner, and three experts in measurement development 
(Welch et al., 2013).  
Confidence in managing chronic disease was assessed using the Self-Efficacy for 
Managing Chronic Disease Scale (SEMCDS)-6-item scale that uses a 10-point Likert scale. A 
sum score is computed; higher scores indicate greater confidence with managing chronic disease. 
Scores range from 6 to 60. Cronbach’s α was reported as .91 (Lorig , Sobel, Ritter, Laurent, & 
Hobbs, 2001), and was .88 for this study.  
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Analysis 
Data were analyzed using SPSS version 22.0. Composites for each survey were 
calculated if they were at least 80% complete and missing values were replaced with the mean of 
that participant’s valid response. Seven KiKS surveys were eliminated from the final analysis 
due to missing data with 10 items. Descriptive statistics analyzed demographic characteristics 
across the CKD stages. Group differences in patient activation and HRQoL, knowledge, skills, 
and confidence across CKD stages were analyzed using Kruskal-Wallis H test, with an alpha 
level of .05. Post hoc testing used Mann-Whitney U tests for pairwise differences, with a 
Bonferroni’s alpha level of .008 (.05/6 pairwise comparisons). Given the small CKD stage 1 
sample size (n = 3), data analyses for CKD stages 1 and 2 were conducted separately and 
together without statistical differences and thus were combined for data analysis.  
 Results   
All participants had diagnoses of DM, HTN and CKD, of which 43 (50.58%) were 
female. The mean age was 63.21years (SD = 13.11) with an age range from 28 – 93 years old. 
Patients with CKD stage 3 were the most activated (M = 64.86, SD = 18.14), followed by CKD 
stage 4 (M = 63.63, SD = 13.29), and early CKD stages 1 and 2 (M = 62.08, SD = 11.20) 
compared to patients with kidney failure (CKD stage 5), who were the least activated (M = 
58.04, SD = 13.46). See Table 1 for additional demographic data including clinical variables. 
Aim: To examine if differences exist in patient activation and HRQol, knowledge, SM, and 
confidence across CKD stages.  
 Results from Kruskal-Wallis tests found significant group differences in patient 
activation and anxiety (Table 2) and BP SM (Table 3). Post hoc testing using the Mann-Whitney 
U test and a Bonferroni adjusted alpha level of .008 found patients reported less BP SM in early 
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CKD stages 1 and 2 compared with CKD stage 4 (z = -2.991, p = .003). Moreover, patients 
reported more anxiety in early CKD stages 1 and 2 than in CKD stage 3 (z = -2.798, p = .005).  
Discussion  
Results from our study suggest that activating patients in early to mid CKD stages may 
assist patients with maintaining their physical function and satisfaction with their social role until 
kidney failure. Depression and anxiety were highest in early CKD stages, with significant group 
difference between CKD stages 1 and 2, and CKD stage 3. For example, participants with CKD 
stage 3 reported feeling less fearful and uneasy and not as overwhelmed as their cohorts in CKD 
stages 1 and 2. This may be due to patients recognizing drastic changes to their daily routine, 
such as daily CKD SM needed to preserve kidney function and delay disease progression. This 
daily routine may be overwhelming to patients diagnosed in the early stages, who are 
asymptomatic. Overall, healthcare providers may assist their patients with developing strategies 
for maintaining their HRQoL as CKD progresses. For example, the Centers for Medicare and 
Medicaid Services require dialysis units to routinely assess HRQoL, but regular assessment in 
earlier CKD stages is not required.  
The declining PAM mean from CKD stage 3 to stage 5 may suggest an interesting 
dynamic that patients in CKD stage 4 may need re-boosting of their knowledge, skills and 
confidence as the difficulty of CKD SM increases with progression to kidney failure. Or it may 
suggest that patients lose their interest in or ability to actively self-manage their kidney disease in 
advance stages.  
The kidney knowledge mean score of 62.5 in our study was lower than a reference mean 
of 66.0 from a prior study of patients diagnosed across all five CKD stages (Wright et al., 2011). 
Our mean was unexpectedly low given that 81.5% of our participants were in CKD stages 3-5. 
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The disease-specific knowledge score in our study did not trend upward with disease 
progression, which suggests the need for patient education remediation across all CKD stages. It 
is interesting to note that a participant from our study stated, “Maybe a little education about the 
disease might have made a difference. I didn’t fully understand the function of the kidneys,” 
when asked what could have been done differently to help patients better self-manage their 
CKD. Educating patients early in their disease process regarding BP SM, like taking BP readings 
and medications daily may delay complication from developing, such as heart disease associated 
with CKD. 
Exhibiting confidence assists patients with building SM skills, such as effectively 
communicating with members of their healthcare team (Curtin et al., 2008) and developing 
adherent behaviors over time (Barnason et al., 2003; Tsay, 2003). Patients with greater activation 
reported better SM of their kidney disease and confidence with managing chronic disease. For 
example, participants in CKD stage 4 scored significantly higher than their cohorts in CKD 
stages 1 and 2 with their BP SM that included diet, exercise, stress, and medication management. 
This information supports the need for healthcare providers to assist their patients with building 
confidence in their ability to daily manage their health care. Without intervention the daily 
challenges of monitoring HTN to preserve kidney health may impact patients’ activation levels. 
In conclusion, the results from this study indicate higher activation is associated with 
positive patient outcomes. More activated patients with CKD stage 3 reported the greatest 
number of positive outcomes followed by those with CKD stages 4 and 5. These findings support 
the need to investigate the effects of patient activation on preserving kidney function and 
maintaining overall kidney health. Building relationships with patients and engaging them in 
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their health care may facilitate patients’ development of daily SM behaviors that aid in slowed 
disease progression.  
Limitations 
 This study begins to address the gap in scientific evidence related to differences in patient 
activation and HRQoL, knowledge, SM, and confidence in CKD. It is important to note that 
causality cannot be determined with a descriptive study. A small sample size (N = 85) posed a 
challenge when analyzing data and comparing results across all 5 stages. A very small sample 
size in CKD stage 1 (n = 3) made it necessary to combine with CKD stage 2 (n = 12) for 
statistical purposes. However, these two stages are similar from a symptoms and treatment 
standpoint. Plus, albuminuria conventional units, which could have provided better separation 
between CKD stages 1 and 2, were not standardized throughout all clinic sites and thus were not 
used in data analysis. Knowledge of DM was not assessed. Last, data were collected from 
patients’ self-reports and participants may have provided socially desirable responses rather than 
actual behaviors.  
 Potential internal threats to validity include limitations with the instruments used, 
especially the Blood Pressure Self-Care Scale (revised) with a Cronbach’s α of .57, along with 
the addition of new surveys and the research assistants later in the study. There may have been 
biases with the different approaches to data collection. It is possible that a confounding effect 
with the face to face interviews only in CKD stage 5 allowed the participants to think longer 
about a response than participants answering the questions over the telephone, or responding via 
hard copies and Survey Monkey.  
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Implications for Nursing  
Nurses play a vital role in disease-specific SM education to promote patients’ active 
involvement in their daily health care. Nurses are instrumental in enhancing patients’ knowledge 
about the risk factors associated with CKD progression, such as uncontrolled BP/BG levels. 
Nurses can assist patients with developing SM skills, such as problem-solving dietary challenges 
during the holidays, or with daily decision-making when using salt or sugar in cooking. Nurses 
can assist patients to devise activity action plans that incorporate setting goals with subsequent 
evaluation; assist patients with building confidence, and reinforce patients’ use of SM skills. 
Additionally, nurses may provide social modeling by connecting their patients with community 
resources, like support groups for individuals with diabetes that will continue to provide support 
and education necessary for long-term behavior change. 
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Table 1: Characteristics of Study Participants 
 
Characteristic  n (%) M (SD) Median 
Race 
   Caucasian 
   African American 
   Hispanic 
   Asian 
84 
71 (85) 
10 (12) 
2 (2) 
1 (1) 
  
Marital status  
   Married 
   Not married 
84 
48 (57) 
36 (43) 
  
Education  
   12th grade or less 
   Greater than 12th grade 
82 
31 (38) 
51 (62) 
  
Employment 
   Yes  
   No  
   Retired 
83 
20 (24) 
17 (21) 
46 (55) 
  
Currently smoking 
   Yes 
   No 
78 
17 (22) 
61 (78) 
  
CKD stage 
   Stage 1 
   Stage 2 
   Stage 3 
   Stage 4 
   Stage 5,   
     no dialysis 
   Stage 5,  
     receiving hemodialysis 
81 
3 (4) 
12 (15) 
30 (37) 
15 (19) 
2 (2) 
 
19 (23) 
Age 
 
57.07 (10.04)a 
64.45 (12.80) 
   67.71 (8.39) 
 
 
64.10 (15.59)b 
Age 
 
57.00 
65.00 
68.00 
 
 
62.00 
Patient activation 
   Level 1 
   Level 2 
   Level 3 
   Level 4 
85 
8 (10) 
24 (28) 
24 (28) 
29 (34) 
  
Length of DM 
   Range: 6 months – 55 years 
85 17.92 (12.64) 15.00 
Length of HTN 
   Range: 1 – 50 years     
85 18.08 (12.96) 15.50 
Length of CKD 
   Range: 1 month – 50 years  
85 8.03 (9.66) 5.00 
Length of receiving 
hemodialysis (in years) 
   Range: 1.5 – 19 years  
19 (22) 5.07 (4.51) 3.00 
a CKD stages 1,2 combined  
b CKD stage 5, including participants receiving and not receiving hemodialysis 
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Table 2: Means and Standard Deviations with Kruskal-Wallis Test of Differences in Patient 
Activation and Health-Related Quality of Life across CKD Stages 
 
 Stages 1,2 
(n=15) 
 
Stage 3 
(n=29) 
Stage 4 
(n=15) 
Stage 5 
(n=21) 
2 p 
Variable 
 
M (SD) M (SD) M (SD) M (SD)   
Patient 
Activation 
62.08 (11.20) 64.86 (18.14) 63.63 (13.29) 58.04 (13.46) 3.62 .306 
 
Physical 
Function 
 
40.61 (9.24) 
 
40.20 (9.39) 
 
37.03 (9.45) 
 
37.51 (11.01) 
 
1.50 
 
.682 
       
Fatigue 54.29 (12.06) 51.19 (9.87) 53.90 (12.57) 56.50 (10.78) 2.05 .563 
       
Anxiety 54.69 (10.72) 45.92 (8.61) 44.65 (7.92) 48.75 (9.20) 10.69  .014* 
       
Depression 53.64 (12.59) 47.17 (8.57) 44.43 (5.87) 51.06 (9.54) 7.11 .068 
       
Sleep 
Disturbance 
53.19 (9.38) 50.05 (8.29) 50.86 (8.81) 48.97 (7.65) 1.38 .710 
       
Satisfaction 
Social Role 
45.81 (11.04) 49.45(9.47) 52.69 (10.84) 48.09 (9.52) 3.59 .310 
       
Pain 
Interference 
 
58.95 (12.73) 52.63 (11.06) 50.48 (10.84) 56.03 (9.00) 4.94 .176 
Note. df = 3 for all Kruskal-Wallis tests. 
*p < .05, two-tailed. 
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Table 3: Means and Standard Deviations with Kruskal-Wallis Test of Differences in Patient 
Activation and Knowledge, Skills, and Confidence across CKD Stages  
 
 Stages 1,2 
(n=15) 
 
Stage 3 
(n=29) 
Stage 4 
(n=15) 
Stage 5 
(n=21) 
2 p 
Variable 
 
M (SD) M (SD) M (SD) M (SD)   
       
Kidney 
knowledge 
67.56 (12.78) 53.33 (21.90) 61.22 (13.43) 66.33 (16.92) 2.90 .407 
       
BP 
knowledge 
5.56 (.75) 5.76 (.76) 5.72 (.85) 5.69 (1.07) .82 .845 
       
BP self-care 4.64 (.74) 5.27 (.67) 5.54 (.72) 5.24 (.74) 10.05  .018* 
       
CKD SM 
skillsa 
3.67 (.70) 3.74 (.67) 3.69 (.37) ------------- .11 .948 
       
Confidence 6.11 (1.64) 6.80 (1.91) 7.49 (1.42) 7.31 (2.19) 2.06 .561 
       
Note. df = 3 for all Kruskal-Wallis tests. 
aThe CKD SM Scale was not designed for patients with kidney failure.  
*p < .05, two-tailed. 
 
 
